# Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Study · id `cardio:ct-nct01768559` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01768559](<https://clinicaltrials.gov/study/NCT01768559>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01768559

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 894 participants.

## Technical summary

Registry record NCT01768559. Randomized; no masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2014-12 (actual). Results posted on 2017-01-04.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 894 participants (enrolled count; ClinicalTrials.gov record NCT01768559, source copy `cardio:ctgov-nct01768559-2017-01-04`, retrieved 2026-10-26)
- Start date: 2013-01 (registry gives no type) (ClinicalTrials.gov record NCT01768559, source copy `cardio:ctgov-nct01768559-2017-01-04`, retrieved 2026-10-26)
- Primary completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01768559, source copy `cardio:ctgov-nct01768559-2017-01-04`, retrieved 2026-10-26)
- Completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01768559, source copy `cardio:ctgov-nct01768559-2017-01-04`, retrieved 2026-10-26)
- Results first posted: 2017-01-04 (ClinicalTrials.gov record NCT01768559, source copy `cardio:ctgov-nct01768559-2017-01-04`, retrieved 2026-10-26)
- Countries: United States; Canada; Chile; Czechia; Estonia; France; Germany; Hungary; Italy; Latvia; Lithuania; Mexico; Poland; Romania; Russia; Spain; Ukraine; United Kingdom (ClinicalTrials.gov record NCT01768559, source copy `cardio:ctgov-nct01768559-2017-01-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01768559-2017-01-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients
- Acronym: GetGoal-Duo-2
- Condition: Type 2 Diabetes
- Intervention (Drug): Lixisenatide (AVE0010)
- Intervention (Drug): Insulin glulisine QD
- Intervention (Drug): Insulin glulisine TID
- Intervention (Drug): Insulin Glargine (Mandatory background drug)
- Intervention (Drug): Metformin (Background drug)
- Lead sponsor: Sanofi
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sanofi (`cardio:org-sanofi`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial (`cardio:pubmed-27222510`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: eed81416351900916398ffe8b010ac8dc22d48bcef2eeaa1324643ab8efb442b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
